Displaying 171–180 of 857 results
Jun 20, 2022
Biologist and Father Dedicated to Daughter’s Cure
After Allison’s diagnosis with Usher syndrome type 3, her dad, Jeff Libby, wanted to do everything he could to find her a cure. As a biologist, Jeff started searching for organizations researching blinding diseases like Allison’s, and he found the Foundation Fighting Blindness.
Jun 15, 2022
Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fund
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
Jun 13, 2022
Over Thirty Presentations Highlighted during the 2022 Retinal Cell & Gene Therapy Innovation Summit
In its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.
Jun 6, 2022
Passionate Professional Outreach Volunteer Helping Newly Diagnosed
Jim has always been avid about giving back to others, even after he was diagnosed with retinitis pigmentosa. And in the last few years, he’s begun working with the Foundation to help eye care professionals in the Cincinnati and Northern Kentucky area provide vital resources for their patients with retinal diseases.
May 24, 2022
Luxa Doses First Participant in Clinical Trial of RPE Stem Cells for Dry AMD Patients
The company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
May 23, 2022
Mark Erelli has been a professional musician for the past twenty-three years. He’s always used songwriting to express himself. Since being diagnosed with retinitis pigmentosa, he’s needed music more than ever.
May 20, 2022
Foundation Insights Forum – May 13, 2022
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on May 13, 2022.
May 19, 2022
ProQR’s Sepofarsen Improves Vision Significantly for Girl with LCA10
However, the Phase 2/3 Illuminate trial for sepofarsen didn’t meet its endpoints at 12 months
May 17, 2022
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
The three-month results support the planned launch of the company’s Phase 2/3 Vista trial
May 13, 2022
Enhanced Implantable Miniature Telescope Moving into Clinical Trial for AMD Patients
The device is designed for people with late-stage AMD who have no treatment options